Cargando…

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer

PURPOSE: To investigate the clinicopathological characteristics and prognostic factors of early‐stage breast cancer (EBC) with human epidermal growth factor receptor 2 (HER2)‐low expression. METHODS: The clinicopathological data and follow‐up information of EBC patients with HER2‐low and HER2‐0 expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Qian, Yang, Fan, Liu, YinHua, Zhang, Hong, Zhang, Shuang, Xin, Ling, Xu, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587975/ https://www.ncbi.nlm.nih.gov/pubmed/37772432 http://dx.doi.org/10.1002/cam4.6571

Ejemplares similares

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China
por: Qin, Tao, et al.
Publicado: (2015)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
por: Tarantino, P., et al.
Publicado: (2023)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics
por: Liu, Xiangdong, et al.
Publicado: (2015)

Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
por: Yang, Man, et al.
Publicado: (2023)

mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer
por: Wada, Ryuichi, et al.
Publicado: (2016)

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
por: Xu, Hangcheng, et al.
Publicado: (2022)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
por: Yang, Xin, et al.
Publicado: (2023)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Comprehensive Analysis of the Expression and Prognostic Value of LMAN2 in HER2+ Breast Cancer
por: Zhang, Di, et al.
Publicado: (2022)

Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2008)

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
por: Yang, Fan, et al.
Publicado: (2022)

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2020)

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
por: Elshazly, Ahmed M., et al.
Publicado: (2022)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
por: Song, Ran, et al.
Publicado: (2023)

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients
por: Asgeirsson, Kristjan S, et al.
Publicado: (2007)

Matrix Metalloproteinase-9 as Prognostic Factor for the Treatment of HER-2 Enriched Breast Cancer
por: Khambri, Daan, et al.
Publicado: (2022)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
por: McGranahan, Tresa M., et al.
Publicado: (2022)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
por: Zhou, Shuling, et al.
Publicado: (2023)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Key Genes and Prognostic Analysis in HER2+ Breast Cancer
por: Weng, Yujie, et al.
Publicado: (2021)

Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing
por: Xiang, Hongyu, et al.
Publicado: (2020)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)
por: Xin, Ling, et al.
Publicado: (2022)

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study
por: Liu, Chang-Gen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ibh5bq12kpmleqfmklg9bbildl